Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts

```
                  page images from 1967-1998
 NEWS 28  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS 29  AUG 15  CAplus currency for Korean patents enhanced
 NEWS 30  AUG 25  CA/CAplus, CASREACT, and IFI and USPAT databases
                  enhanced for more flexible patent number searching

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:36:59 ON 27 AUG 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:37:29 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 AUG 2008  HIGHEST RN 1043895-06-2
DICTIONARY FILE UPDATES:  26 AUG 2008  HIGHEST RN 1043895-06-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
```

```
Uploading C:\Program Files\Stnexp\Queries\10551502.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> l1
SAMPLE SEARCH INITIATED 13:38:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    14737 TO ITERATE

 13.6% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       287468 TO   302012
PROJECTED ANSWERS:           22225 TO    26407

L2           50 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10551502\Struc 2.str
```



chain nodes :
13 14 15 16 17 18 19 20 21 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
4-7 6-25 10-13 13-14 13-15 16-17 17-21 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-25 13-14 13-15 16-17 17-21 18-19 18-20
exact bonds :
4-7 10-13

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:Atom

L3   STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3   STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l3
SAMPLE SEARCH INITIATED 13:41:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   532 TO ITERATE

100.0% PROCESSED   532 ITERATIONS   13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 9257 TO   12023
PROJECTED ANSWERS: 44 TO   476

L4   13 SEA SSS SAM L3

=> l3 full
FULL SEARCH INITIATED 13:41:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   9653 TO ITERATE

100.0% PROCESSED   9653 ITERATIONS   264 ANSWERS
SEARCH TIME: 00.00.01

L5   264 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   181.12   181.33

FILE 'CAPLUS' ENTERED AT 13:41:35 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 26 Aug 2008 (20080826/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> l5
L6 23 L5

=> d ibib abs hitstr 1-23

L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:733338 CAPLUS
DOCUMENT NUMBER: 149:79406
TITLE: Preparation of bicyclic acyltryptophanols as effective FSH antagonists
INVENTOR(S): Wortmann, Lars; Menzenbach, Bernd; Koppitz, Marcus; Kosemund, Dirk; Muhn, Hans-Peter; Schrey, Anna; Kuehne, Ronald; Frenzel, Thomas; Liesener, Florian Peter
PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 217pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008071455	A1	20080619	WO 2007-EP11222	20071215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
EP 1956016 A1 20080813 EP 2006-77263 20061215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS
PRIORITY APPLN. INFO.: EP 2006-77263 A 20061215
US 2006-874962P P 20061215
OTHER SOURCE(S): MARPAT 149:79406
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to acyltryptophanols I [Q = monocyclic aryl or heteroaryl; V = cycloalkylene, cycloalkenylene, heterocycloalkylene, heterocycloalkenylene; X = bond, C1-4-alkylene, C2-6-alkenylene, C2-4-alkynylene; W = aryl, heteroaryl; R1 = H, (un)substituted C1-6-alkyl, C3-6-alkenyl, C3-6-alkynyl, C3-7-cycloalkyl, C1-6-alkoxy-(C1-6-alkylene), C3-7cycloalkoxy-(C1-6-alkylene), etc.; R2= H, halogen, CN, SO2Me, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, OCH2Ph (with the hydrocarbons optionally fluorinated one or more times); R3 = H, OH, halogen, NO2, NH2, CN, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, hydroxy-C1-6-alkylene, hydroxy-C2-6-alkenylene, hydroxy-C1-6-alkynylene, C1-6-alkoxy, etc; R4, R5, R6, = H, OH, halogen, NO2, NH2, CN, Ph, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-(C1-6-alkylene), C3-7heterocycloalkyl (wherein the hydrocarbons may be substituted by F, CN, pyrrolidino, morpholino, thiamorpholino, etc.); R7, R8 = H, Me, Et (whereby Me and Et are optionally fluorinated one or more times)]. One process comprises coupling of tryptophanol derivative II with carboxylic acids III via: (a) conversion of said carboxylic acid into an intermediate active ester or carbonyl chloride with a suitable peptide-coupling reagent, or SOCl2, ClC(:O)C(:O)Cl, phosgene or a derivative thereof, where appropriate in the presence of a base; and (b) reacting the active intermediate with tryptophanol. Thus, 6-[3-chloro-4-(methylcarbamoyl)phenyl]-2H-chromene-8-carboxylic acid [(R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amide (IV) was prepared from Me 6-iodo-2H-chromene-8-carboxylate via saponification with KOH in MeOH, amidation with D-tryptophanol in DMF containing EDC and HOBt, and coupling reaction with [3-chloro-4-(methylcarbamoyl)phenyl]boronic acid in EtOH containing aqueous Na2CO3 and catalytic Pd(PPh3)4. The compds. according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis. The physiol. activity of IV was determined [IC50 = 130nm FSH-antagonistic effect in HTRF assay].

IT 1033765-82-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and borohydride reduction of; preparation of bicyclic acyltryptophanols as effective FSH antagonists)

RN 1033765-82-0 CAPLUS

CN Tryptophan, N-[[6-[3-chloro-4-[(methylamino)carbonyl]phenyl]-2,2-dimethyl-2H-1-benzopyran-8-yl]carbonyl]-5,7-difluoro-, ethyl ester (CA INDEX NAME)





IT 1033765-83-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of; preparation of bicyclic acyltryptophanols as
effective FSH antagonists)
RN 1033765-83-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1033763-44-8P 1033763-48-2P 1033763-49-3P
1033763-56-2P 1033763-61-9P 1033763-69-7P
1033763-70-0P 1033763-72-2P 1033763-73-3P
1033764-38-3P 1033764-39-4P 1033764-40-7P
1033764-70-3P 1033765-20-6P 1033765-21-7P
1033765-22-8P 1033765-23-9P 1033765-24-0P
1033765-25-1P 1033765-39-7P 1033765-40-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of bicyclic acyltryptophanols as effective FSH antagonists)
RN 1033763-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-48-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-49-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-56-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033763-69-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-70-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033763-72-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033763-73-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033764-38-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033764-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033764-40-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033764-70-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-20-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-21-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-22-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-23-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-24-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-25-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1033765-39-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033765-40-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1033763-43-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation, FSH antagonistic activity and hydrogenation of; preparation of bicyclic acyltryptophanols as effective FSH antagonists)
RN 1033763-43-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:493007 CAPLUS
DOCUMENT NUMBER: 148:517400
TITLE: Biaryl compounds as serine protease inhibitors and their preparation, and use in the treatment of clotting disorders
INVENTOR(S): Babu, Yarlagadda S.; Rowland, R. Scott; Chand, Pooran; Kotian, Pravin L.; El-Kattan, Yahya; Niwas, Shri
PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA
SOURCE: U.S., 166pp., Cont.-in-part of Appl. No. PCT/US2001/32582.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6699994	B1	20040302	US 2002-127460	20020423
WO 2002034711	A1	20020502	WO 2001-US32582	20011022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040162281	A1	20040819	US 2003-738027	20031218

US 6936719 B2 20050830
PRIORITY APPLN. INFO.: US 2001-281735P P 20010406
WO 2001-US32582 A2 20011022
US 2000-241848P P 20001020
US 2002-127460 A3 20020423
OTHER SOURCE(S): MARPAT 148:517400
GI



I



II

AB Compds. of formula I are useful as inhibitors of trypsin like serin protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compds. could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents. Compds. of formula I E1 and L are independently 5- to 7-membered (un)saturated carbocycle, (un)saturated bicyclic ring, (un)substituted (un)saturated 1-8 hydrocarbon chain; R is CH=CH-R2-. C.tplbond.C-R2, CR2=CH2., etc.; R1 and A are independently H, NO2, CN, halo, N2, C1-8 alkyl, etc.; m is 1 except E1 is a cyclic ring of more than 5 atoms, then m is 1 or higher; R2 is H, halo, (halo)alkyl, (CH2)0-4phenyl, etc.; W is a bond, CHR2, CH=CHR2, OCH2, CCR2=CR2, etc.; E2 is 5- to 7-membered (un)saturated (hetero)cyclic ring, C1-8 alkyl, C2-8 alkenyl, etc.; each X is independently a bond, (un)substituted C1-4 methylene chain, O, S, NH and derivs., etc.; B and B1 are independently H, halo, CN, NH2, (un)substituted C1-8 alkyl, etc.; o is 1 except when L is a cyclic ring of more than 5 atoms, then o is 1 and higher; V and V1 are independently R1, N-alkyl substituted carboxamidyl, etc.; p is 1 except when E2 is a cyclic ring of more than 5 atoms, then p is 1 and higher; and their pharmaceutically acceptable salts and prodrugs thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their serine protease inhibitory activity (some data given).

IT 1021429-82-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of biaryl compds. as serine protease inhibitors useful in the treatment of clotting disorders)

RN 1021429-82-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-[[[4-(aminoiminomethyl)phenyl]amino] carbonyl]-4-[[(2-methylpropyl)amino]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:124784 CAPLUS
DOCUMENT NUMBER: 148:183378
TITLE: Assay for differentiating compounds that modulate the extrinsic and/or intrinsic coagulation pathways
INVENTOR(S): Wang, Xinkang; Hsu, Mei-Yin; Wong, Pancras C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 13pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080026474	A1	20080131	US 2007-782660		20070725
PRIORITY APPLN. INFO.:			US 2006-833674P	P	20060727

AB Methods for differentiating compds. that modulate the extrinsic and/or intrinsic coagulation pathways are provided. Also provided are methods for identifying a compound that modulates the extrinsic coagulation pathway. In addition, methods for determining an effective dosage of an anticoagulant in a patient are provided.
IT 1004551-41-0
RL: PAC (Pharmacological activity); BIOL (Biological study)
(assay for differentiating compds. that modulate extrinsic and/or intrinsic coagulation pathways)
RN 1004551-41-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[(2S,4R)-6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:43636 CAPLUS
DOCUMENT NUMBER: 148:121398
TITLE: Cycloalkylcarboxamides and related compounds as modulators of ATP-binding cassette transporters and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Hadida Ruah, Sara S.; Miller, Mark T.; Bear, Brian; McCartney, Jason; Grootenhuis, Peter D. J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 422pp., Cont.-in-part of U.S. Ser. No. 647,092.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080009524	A1	20080110	US 2007-824606		20070629
US 20080044355	A1	20080221	US 2006-647092		20061228
PRIORITY APPLN. INFO.:			US 2005-754558P	P	20051228
			US 2006-802580P	P	20060522
			US 2006-647092	A2	20061228

OTHER SOURCE(S): MARPAT 148:121398
GI



I



II

AB Compds. of formula I and pharmaceutically acceptable compns. thereof, are useful as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The invention also relates to methods of treating ABC transporter mediated diseases using compds. of formula I. Compds. of formula I wherein each R1 is independently (un)substituted C1-6 aliphatic, (un)substituted (hetero)aryl, (un)substituted C3-10 cycloaliph. and (un)substituted 4- to 10-membered heterocycloaliph., carboxy, amido, amino, halo and OH provided that at least one of R1 is (un)substituted (hetero)aryl attached to the 3- or 4-position of the Ph ring; R2 is H, (un)substituted C1-6 aliphatic, (un)substituted C3-6 cycloaliph., (un)substituted Ph, and (un)substituted heteroaryl; Ring A is (un)substituted cycloaliph., and (un)substituted heterocycloaliph. where the atoms of ring A adjacent to C* are carbon atoms; R4 is (un)substituted (hetero)aryl; n is 1, 2, 3, 4, and 5; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their ATP-binding cassette transporter modulatory activity (some data given).

IT 945238-88-0P 945241-55-4P 945244-57-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkylcarboxamides and related compds. as modulators of ATP-binding cassette transporters)

RN 945238-88-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2,2'-dimethyl- (CA INDEX NAME)



RN 945241-55-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-chloro-N,2'-dimethyl- (CA INDEX NAME)



RN 945244-57-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2-fluoro-2'-methyl- (CA INDEX NAME)



L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1476060 CAPLUS
DOCUMENT NUMBER: 148:100510

TITLE: Preparation of pyridinylcarboxamide and phenylcarboxamide derivatives as prolyl hydroxylase inhibitors and methods of use
INVENTOR(S): Kawamoto, Richard Masaru
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S. Pat. Appl. Publ., 53pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070299086	A1	20071227	US 2007-821936	20070626
WO 2008002576	A2	20080103	WO 2007-US14832	20070626
WO 2008002576	A3	20080703		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-816522P P 20060626
OTHER SOURCE(S): MARPAT 148:100510
GI



I



II

AB Title compds. I [R and R1 independently = H, (un)substituted H, Ph, or heteroaryl; X = N or CH; Y = H, OH, OMe, or OEt; R9 = H or Me; R2 = OR6 or NR7R8; R6 = H, alkyl, or cycloalkyl; R7 and R8 independently = H, alkyl, cycloalkyl, or taken together form a ring; L = linking 1-3 carbon unit optionally substituted with Me or Et], and their pharmaceutically acceptable salts, are prepared and disclosed as prolyl hydroxylase inhibitors. Thus, e.g., II was prepared by sulfonylation of [(3,5-dihydroxypyridine-2-carbonyl)amino]acetic acid Me ester (preparation given) with trifluoromethanesulfonic acid followed by substitution with 3-chlorophenylboronic acid. I were evaluated in EGLIN 1 assays; e.g., II demonstrated an IC50 value of 2.8 μM. The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compns. which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

IT 1007378-37-1P 1007378-58-6P 1007378-62-2P
1007378-65-5P 1007378-92-8P 1007379-14-7P
1007379-17-0P 1007379-20-5P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(propehtic drug candidate; preparation of pyridinylcarboxamide and phenylcarboxamide derivs. as prolyl hydroxylase inhibitors and methods of use)

RN 1007378-37-1 CAPLUS

CN Glycine, N-[[3'-(aminocarbonyl)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1007378-58-6 CAPLUS
CN Glycine, N-[[3'-(acetylamino)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1007378-62-2 CAPLUS
CN Glycine, N-[[3-hydroxy-3'-[(1-oxopropyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1007378-65-5 CAPLUS
CN Glycine, N-[[3'-[(cyclopropylcarbonyl)amino]-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1007378-92-8 CAPLUS
CN Glycine, N-[[3'-(aminocarbonyl)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)



RN 1007379-14-7 CAPLUS
CN Glycine, N-[[3'-(acetylamino)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-
(CA INDEX NAME)



RN 1007379-17-0 CAPLUS
CN Glycine, N-[[3-hydroxy-3'-[(1-oxopropyl)amino][1,1'-biphenyl]-4-
yl]carbonyl]- (CA INDEX NAME)



RN 1007379-20-5 CAPLUS
CN Glycine, N-[[3'-[(cyclopropylcarbonyl)amino]-3-hydroxy[1,1'-biphenyl]-4-
yl]carbonyl]- (CA INDEX NAME)



L6 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:846121 CAPLUS
DOCUMENT NUMBER: 147:211534

TITLE: Cycloalkylcarboxamides and related compounds as modulators of ATP-binding cassette transporters and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Ruah, Sara S. Hadida; Miller, Mark T.; Bear, Brian; McCartney, Jason; Grootenhuis, Peter D. J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 249pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007087066	A2	20070802	WO 2006-US49412	20061228
WO 2007087066	A3	20071025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006336504	A1	20070802	AU 2006-336504	20061228

PRIORITY APPLN. INFO.:			
US 2005-754558P	P	20051228	
US 2006-802580P	P	20060522	
WO 2006-US49412	W	20061228	

OTHER SOURCE(S): MARPAT 147:211534

GI



I



II

AB Compds. of formula I and pharmaceutically acceptable compns. thereof, are useful as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The invention also relates to methods of treating ABC transporter mediated diseases using compds. of formula I. Compds. of formula I wherein each R1 is independently (un)substituted C1-6 aliphatic, (un)substituted (hetero)aryl, (un)substituted C3-10 cycloaliph. and (un)substituted 4- to 10-membered heterocycloaliph., carboxy, amido, amino, halo and OH provided that at least one of R1 is (un)substituted (hetero)aryl attached to the 3- or 4-position of the Ph ring; R2 is H, (un)substituted C1-6 aliphatic, (un)substituted C3-6 cycloaliph., (un)substituted Ph, and (un)substituted heteroaryl; Ring A is (un)substituted cycloaliph., and (un)substituted heterocycloaliph. where the atoms of ring A adjacent to C* are carbon atoms; R4 is (un)substituted (hetero)aryl; n is 1, 2, 3, 4, and 5; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their ATP-binding cassette transporter modulatory activity (some data given).

IT 945238-88-0P 945241-55-4P 945244-57-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkylcarboxamides and related compds. as modulators of ATP-binding cassette transporters)

RN 945238-88-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2,2'-dimethyl- (CA INDEX NAME)



RN 945241-55-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-chloro-N,2'-dimethyl- (CA INDEX NAME)



RN 945244-57-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2-fluoro-2'-methyl- (CA INDEX NAME)



L6 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:327723 CAPLUS
DOCUMENT NUMBER: 146:358864

TITLE: Preparation of heterocyclyl biphenylcarboxamides for treatment of hepatitis C virus (HCV) infection.

INVENTOR(S): Wheelhouse, Christopher James; Thomas, Alexander James Floyd; Bushnell, David John; Lumley, James; Salter, James Iain; Carter, Malcolm Clive; Mathews, Neil; Pilkington, Christopher John; Angell, Richard Martyn

PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 170pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031791	A1	20070322	WO 2006-GB3469	20060918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006290442	A1	20070322	AU 2006-290442	20060918
CA 2621364	A1	20070322	CA 2006-2621364	20060918
EP 1940786	A1	20080709	EP 2006-779478	20060918
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2007138242	A1	20071206	WO 2007-GB1024	20070321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
MX 200803269	A	20080409	MX 2008-3269	20080307
KR 2008050490	A	20080605	KR 2008-708964	20080415

PRIORITY APPLN. INFO.:

GB 2005-18971	A	20050916
GB 2006-10663	A	20060530
GB 2006-10664	A	20060530
WO 2006-GB3469	W	20060918

OTHER SOURCE(S): MARPAT 146:358864

GI



I

AB Title compds. [I; R1 = alkyl, A1, L1A1, A1A11, L1A1A11, A1L1A11, A1Y1A11, A1Het1A11, L1A1Y1A11, L1A1Het1A11, L1Het1A1, L1Y1A1, L1Y1Het1A1, L1Het1Y1A1, L1Y1Het1L11, A1Y1Het1A11, A1Het1Y1A11, A1Het1L1A11, A1L1Het1A11, L1Het1L11; A, B = bond, CONR', NR'CO, NR'CO2, CO, NR'CONR'', NR'SO2, SO2, NR', NR'COCO, CO2, alkylene-NR', hydroxyalkylene-NR'; R', R'' = H, alkyl; R2, R3 = alkyl, alkoxy, haloalkyl, haloalkoxy, halo; m, n = 0, 1; R4 = alkyl, A4, L4A4, A4A41, L4A4A41 , A4L4A41, A4Y4A41, A4Het4A41, L4A4Y4A41, L4A4Het4A41, L4Het4A4, L4Y4A4, L4Y4Het4A4, L4Het4Y4A4, L4Y4Het4L41, A44Het4A41, A4Het4Y4A41, A4Het4L4A41, A4L4HetA41, L4Het4L41; A1, A4, A11, A41 = Ph, 5-10 membered heteroaryl, heterocyclyl, carbocyclyl; L1, L4 = alkylene, hydroxyalkylene; Y1, Y4 = CO, SO, SO2; L11, L41 = H, alkyl; Het1, Het4 = O, S, NR'; the Ph, heteroaryl, heterocyclyl and carbocyclyl moieties in R1, R4 being optionally substituted and/or fused to Ph, 5-10 membered heteroaryl, heterocyclyl], were prepared Thus, 6-methylbiphenyl-3,,4'-dicarboxylic acid 4'-[(4-isoxazol-5-ylphenyl)amide] 3-[(4-morpholin-4-ylphenyl)amide] (preparation outlined) inhibited HCV replication with IC50 <1 μM.

IT 929892-30-8 929892-31-9 929892-32-0
929892-33-1 929892-34-2 929893-13-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of heterocyclyl biphenylcarboxamides for treatment of hepatitis C virus infection)

RN 929892-30-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-(3-methoxyphenyl)-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929892-31-9 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-1H-indazol-6-yl-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929892-32-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-(3-bromophenyl)-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929892-33-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-[4-(5-isoxazolyl)phenyl]-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929892-34-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-[(3-chlorophenyl)methyl]-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929893-13-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-[(cyclopropylcarbonyl)amino]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]-2,4'-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:175569 CAPLUS
DOCUMENT NUMBER: 146:251733
TITLE: Preparation of acyltryptophanols as FSH antagonists
INVENTOR(S): Wortmann, Lars; Cleve, Arwed; Muhn, Hans-Peter; Langer, Gernot; Schrey, Anna; Kuehne, Ronald; Menzenbach, Bernd; Koppitz, Marcus; Kosemund, Dirk
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 404pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017289	A2	20070215	WO 2006-EP7949	20060808
WO 2007017289	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

DE 102005038632	A1	20070215	DE 2005-102005038632	20050810
DE 102005038632	B4	20080327		
CA 2618888	A1	20070215	CA 2006-2618888	20060808
EP 1912970	A2	20080423	EP 2006-776768	20060808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070060573	A1	20070315	US 2006-501228	20060809

PRIORITY APPLN. INFO.: DE 2005-102005038632A 20050810
US 2005-706743P P 20050810
WO 2006-EP7949 W 20060808

OTHER SOURCE(S): MARPAT 146:251733
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; R3 = H, OH, halo, etc.; R4-R6 = H, OH, halo, etc.; or R5 and R6 may together form heterocycloalkyl, cycloalkyl; R7, R8 = H, Me, Et (Me and Et may be fluorinated); Q, W = (hetero)aryl; X = a bond, alkylene, alkenylene, etc.; Y = a bond, alkylene] which are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis, were prepared E.g., a multi-step synthesis of II, starting from 5-bromo-DL-tryptophan, was given. II showed IC50 of 7 μM when tested for FSH-antagonistic effect in the HTRF assay. Pharmaceutical composition comprising the compound I is disclosed.

IT 925937-80-0P 925937-83-3P 925937-85-5P
925939-41-9P 925939-55-5P 925939-68-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acyltryptophanols as FSH antagonists)

RN 925937-80-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 925937-83-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[2-(5-fluoro-1H-indol-3-

yl)-1-(hydroxymethyl)ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)



RN 925937-85-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-[(1-methyl-1H-indol-3-yl)methyl]ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 925939-41-9 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 925939-55-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[2-(5-fluoro-1H-indol-3-yl)-1-(hydroxymethyl)ethyl]-4-propoxy- (CA INDEX NAME)



RN 925939-68-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-[(1-methyl-1H-indol-3-yl)methyl]ethyl]-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1096119 CAPLUS
DOCUMENT NUMBER: 145:438417
TITLE: Substituted 3,4'-biphenyldicarboxamides as p38 kinase inhibitors, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Boehm, Jeffrey C.; Callahan, James Francis; Wan, Zehong; Yan, Hongxing
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 130pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110173	A2	20061019	WO 2005-US35743	20051005
WO 2006110173	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
EP 1805132 A2 20070711 EP 2005-857821 20051005
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
JP 2008515898 T 20080515 JP 2007-535764 20051005
US 20080051416 A1 20080228 US 2007-576748 20070405
PRIORITY APPLN. INFO.: US 2004-616065P P 20041005
US 2005-719729P P 20050922
WO 2005-US35743 W 20051005
OTHER SOURCE(S): MARPAT 145:438417
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I, and their pharmaceutically acceptable derivs., and their use as pharmaceuticals, particularly as p38 kinase inhibitors, are disclosed [wherein R1 = H, (un)substituted cyclo/alkyl, hetero/aryl, heterocyclyl; R2 = H, (un)substituted cyclo/alkyl; or R2N(CH2)mR1 = 4- to 6-membered heterocyclyl; R3 = halo, Me; R8 = H, (un)substituted cyclo/alkyl, Ph, heteroaryl; X, Y = independently H, Me, halo; Z = (CH2)qCOOR9, (CH2)qNR9R10; R9, R10 = independently H, (un)substituted alkyl, hetero/aryl, etc.; or R9NR10 = 5- to 6-membered ring; m, q = independently 0-4; n = 0-2; ; or pharmaceutically acceptable salts and derivs. thereof]. Thus, Pd-coupling of Me 2-bromo-5-[[(2,2-dimethylpropyl)amino]carbonyl]benzoate (preparation given) with 4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid followed by amidation of the biphenylcarboxylic acid with 2-aminoethanol gave dicarboxamide II. In a fluorescence anisotropy kinase binding assay, II had a pIC50 value of <4.8.

IT 913002-55-8P 913002-56-9P 913002-57-0P
913002-63-8P 913002-68-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of biphenyldicarboxamides as p38 kinase inhibitors)

RN 913002-55-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[[(2,2-dimethylpropyl)amino]carbonyl]-5'-[[(2-hydroxyethyl)amino]carbonyl]-2'-methyl-, methyl ester (CA INDEX NAME)



RN 913002-56-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-2'-methyl-, methyl ester (CA INDEX NAME)



RN 913002-57-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-2'-methyl- (CA INDEX NAME)



RN 913002-63-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[[(2,2-dimethylpropyl)amino]carbonyl]-5'-[[(2-hydroxyethyl)amino]carbonyl]-2'-methyl- (CA INDEX NAME)



RN 913002-68-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl- (CA INDEX NAME)



IT 913001-79-3P 913001-80-6P 913001-81-7P
913001-82-8P 913001-83-9P 913001-84-0P
913001-85-1P 913001-86-2P 913001-87-3P
913001-88-4P 913001-89-5P 913001-90-8P
913001-91-9P 913001-92-0P 913001-93-1P
913001-94-2P 913001-95-3P 913001-96-4P
913001-97-5P 913001-98-6P 913001-99-7P
913002-00-3P 913002-01-4P 913002-02-5P
913002-03-6P 913002-04-7P 913002-05-8P
913002-06-9P 913002-08-1P 913002-09-2P
913002-10-5P 913002-11-6P 913002-12-7P
913002-13-8P 913002-14-9P 913002-15-0P
913002-16-1P 913002-17-2P 913002-18-3P
913002-19-4P 913002-20-7P 913002-21-8P
913002-22-9P 913002-23-0P 913002-24-1P
913002-25-2P 913002-26-3P 913002-27-4P
913002-28-5P 913002-29-6P 913002-30-9P
913002-31-0P 913002-32-1P 913002-33-2P
913002-34-3P 913002-35-4P 913002-36-5P
913002-37-6P 913002-38-7P 913002-39-8P
913002-40-1P 913002-41-2P 913002-42-3P
913002-43-4P 913002-44-5P 913002-45-6P
913002-46-7P 913002-47-8P 913002-48-9P
913002-49-0P 913002-50-3P 913002-51-4P
913002-52-5P 913002-53-6P 913002-54-7P
913002-58-1P 913002-59-2P 913002-60-5P
913002-61-6P 913002-62-7P 913002-64-9P
913002-65-0P 913002-66-1P 913002-67-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biphenyldicarboxamides as p38 kinase inhibitors)

RN 913001-79-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-[(1S)-1-cyclohexylethyl]-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-80-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-[(4-hydroxy-1-piperidinyl)carbonyl]-6-methyl- (CA INDEX NAME)



RN 913001-81-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-propyl- (CA INDEX NAME)



RN 913001-82-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-[2-(dimethylamino)ethyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913001-83-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-84-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(1-methylethyl)- (CA INDEX NAME)



RN 913001-85-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[(3-oxo-1-piperazinyl)carbonyl]- (CA INDEX NAME)



RN 913001-86-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[(2S)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-87-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[(2R)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-88-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl-N3'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-89-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-amino-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)



RN 913001-90-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-[(1S)-1,2-dimethylpropyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-91-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-[(1R)-1,2-dimethylpropyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-92-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(2-methylpropyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-93-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-(cyclopropylmethyl)-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-94-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(3-methylbutyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-95-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-N3'-(3,5-dimethyl-1H-pyrazol-4-yl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-96-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-1,2,4-thiadiazol-5-yl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-97-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-1H-pyrazol-3-yl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-98-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(3-methyl-5-isothiazolyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913001-99-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-3-isoxazolyl-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-00-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclohexyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-01-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2,N3'-bis(2-thiazolyl)- (CA INDEX NAME)



RN 913002-02-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-phenyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-03-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl-N3'-[(1S)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-04-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4,N4-diethyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-05-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-[(1S)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-06-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2,N4-bis(2-thiazolyl)- (CA INDEX NAME)



RN 913002-08-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-phenyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-09-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-cyclohexyl-N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-10-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-11-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-1H-pyrazol-3-yl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-12-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(3,5-dimethyl-1H-pyrazol-4-yl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-13-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-1,2,4-thiadiazol-5-yl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-14-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(1R)-1,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-15-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(1S)-1,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-16-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(cyclopropylmethyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-17-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 913002-18-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-[(1R)-1-phenylethyl]-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-19-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-(phenylmethyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-20-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(cyclohexylmethyl)-N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-21-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-(2-methylpropyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-22-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[3-(dibutylamino)propyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-23-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[3-(dimethylamino)-2,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-24-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-(3-methylbutyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-25-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(1-ethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-26-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(3,4-dimethylphenyl)methyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-27-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-N4,6'-dimethyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-28-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-[2-(1-pyrrolidinyl)ethyl]-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-29-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-30-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-cyclopentyl-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-31-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-(cyclohexylmethyl)-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-32-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-phenyl- (CA INDEX NAME)



RN 913002-33-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-(3,4-difluorophenyl)-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-34-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-

dimethylpropyl)-5'-fluoro-N2-(4-fluorophenyl)-6'-methyl- (CA INDEX NAME)



RN 913002-35-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 913002-36-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-(3-ethoxypropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-37-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-(5-hydroxypentyl)-6'-methyl- (CA INDEX NAME)



RN 913002-38-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[3-(1H-imidazol-1-yl)propyl]-6'-methyl- (CA INDEX NAME)



RN 913002-39-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 913002-40-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-[2-[4-(aminosulfonyl)phenyl]ethyl]-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-41-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-[3-(dibutylamino)propyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-42-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 913002-43-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 913002-44-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-(5-cyanopentyl)-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-45-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-

dimethylpropyl)-5'-fluoro-6'-methyl-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 913002-46-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)



RN 913002-47-8 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 913002-48-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-[(1-ethyl-2-pyrrolidinyl)methyl]-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-49-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(2S)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-50-3 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(2R)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-51-4 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(1S)-1-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-52-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-

N3'-[(1R)-1-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-53-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(4-fluorophenyl)methyl]-6'-methyl- (CA INDEX NAME)



RN 913002-54-7 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[[[(phenylmethyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 913002-58-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl- (CA INDEX NAME)



RN 913002-59-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-60-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-(3-hydroxypropyl)-6'-methyl- (CA INDEX NAME)



RN 913002-61-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 913002-62-7 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-3-pyridinyl- (CA INDEX NAME)



RN 913002-64-9 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-N3'-(2-hydroxyethyl)-6'-methyl- (CA INDEX NAME)



RN 913002-65-0 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-(2-hydroxyethyl)-6'-methyl- (CA INDEX NAME)



RN 913002-66-1 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-(3-hydroxypropyl)-6'-methyl- (CA INDEX NAME)



RN 913002-67-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-3-pyridinyl- (CA INDEX NAME)



IT 776315-27-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of biphenyldicarboxamides as p38 kinase inhibitors)
RN 776315-27-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-formyl-6-methyl- (CA INDEX NAME)



L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927166 CAPLUS
DOCUMENT NUMBER: 141:395428
TITLE: Biarylmethyl indolines, indoles, and tetrahydroquinolines, useful as serine protease inhibitors, and particularly as anticoagulants, and their preparation, pharmaceutical compositions, and use.
INVENTOR(S): Smallheer, Joanne M.; Quan, Mimi L.; Wang, Shuaige; Bisacchi, Gregory S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094372	A2	20041104	WO 2004-US11856	20040415
WO 2004094372	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040220206	A1	20041104	US 2004-824025	20040414
US 7129264	B2	20061031		
EP 1633716	A2	20060315	EP 2004-750251	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006523716	T	20061019	JP 2006-513080	20040415

PRIORITY APPLN. INFO.:

US 2003-463452P	P	20030416
US 2004-824025	A	20040414
WO 2004-US11856	W	20040415

OTHER SOURCE(S): MARPAT 141:395428
GI



I



II

AB The invention provides compds. I or stereoisomers, pharmaceutically acceptable salts or hydrates, or prodrugs thereof [wherein: W = (un)substituted CH2CH2, CH:CH, CH:N, or CH2CH2CH2; L1 = CH2, CH2CH2, CH2S(O)0-2, or CH2C(O); L2 = bond, (un)substituted CH2, CH2CH2, O, NH, C(O), S(O)0-2, CH2C(O), C(O)CH2, CH2O, OCH2, CH2NH, NHCH2, CH2S(O)0-2, S(O)0-2CH2, C(O)O, OC(O), C(O)NH, NHC(O), S(O)NH, S(O)2NH, NHS(O), or NHS(O)2; A = (un)substituted C3-10 carbocycle or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; B = (un)substituted alk(en/yn)yl, C3-10 carbocycle, or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; X = (independently) (un)substituted CH or N]. I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, the invention relates to compds. that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compns. comprising I, and methods of treating thromboembolic and/or inflammatory disorders using I. I had Ki values of ≤ 15 μM in assays for Factor XIa and plasma kallikrein, thereby confirming their utility as effective inhibitors of these entities. Approx. 115 compds. I and various intermediates were prepared For instance, 5-cyanoindole was reduced to 5-cyanoindoline with NaBH3CN (40%) or with Et3SiH (77%). Then, Suzuki coupling of 2-IC6H4CO2Me with 2-OCHC6H4B(OH)2 gave 83% 2-OCHC6H4-C6H4CO2Me-2, which underwent reductive alkylation with 5-cyanoindoline (86%). The obtained 1-substituted 5-cyanoindoline was converted to the corresponding 5-amidoxime, which was reduced by Zn in AcOH to give the 5-amidine (18.5%). Alkaline saponification of the ester moiety gave
invention compound II, isolated as the bis(trifluoroacetate) salt.

IT 787631-06-5P, 2'-(3-Benzyl-5-carbamimidoylindol-1-ylmethyl)-4-

carbamoyl-5'-(methylcarbamoyl)biphenyl-2-carboxylic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biarylmethyl indolines, indoles, and tetrahydroquinolines as serine protease inhibitors and anticoagulants)
RN 787631-06-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-2'-[[5-(aminoiminomethyl)-3-(phenylmethyl)-1H-indol-1-yl]methyl]-5'-[(methylamino)carbonyl]- (CA INDEX NAME)



L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:872774 CAPLUS
DOCUMENT NUMBER: 141:349930
TITLE: Preparation of biphenylcarboxylic amide derivatives as p38 kinase inhibitors
INVENTOR(S): Aston, Nicola Mary; Bamborough, Paul; Jones, Katherine Louise; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089874	A1	20041021	WO 2004-EP3774	20040407

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004228199 A1 20041021 AU 2004-228199 20040407
CA 2521228 A1 20041021 CA 2004-2521228 20040407
EP 1608616 A1 20051228 EP 2004-726134 20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
BR 2004008727 A 20060307 BR 2004-8727 20040407
JP 2006523194 T 20061012 JP 2006-505071 20040407
MX 2005PA10521 A 20051214 MX 2005-PA10521 20050929
US 20070129354 A1 20070607 US 2005-551502 20050930
PRIORITY APPLN. INFO.: GB 2003-8186 A 20030409
WO 2004-EP3774 A 20040407
OTHER SOURCE(S): MARPAT 141:349930

GI



I



II

AB Title compds. represented by the formula I [wherein R1 = H, alkenyl, (un)substituted (cyclo)alkyl, Ph, heteroaryl; R2 = H, (un)substituted alkyl, alkylcycloalkyl or R1R2 = (un)substituted (hetero)cyclic ring; R3 = Me or Cl; R4 = (un)substituted carbonylaminoalkyl, carbamoyl(alkyl); X, Y = independently H, Me, halo; Z = alkylhydroxy, alkylamino, alkyl, etc.; m = 0-4; n = 1; and pharmaceutically acceptable derivative thereof] were prepared as p38 kinase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of Me 3-hydroxy-4-iodobenzoate with 2-chloro-N,N-dimethylethylamine. I were tested for p38 inhibition in fluorescence anisotropy kinase binding assay with IC50 values of less than 10 μM. Thus, I and their pharmaceutical compns. are useful as p38 kinase inhibitors for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

IT 776313-96-3P 776313-97-4P 776313-99-6P
776314-00-2P 776314-01-3P 776314-03-5P
776314-44-4P 776314-68-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)

RN 776313-96-3 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)



RN 776313-97-4 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)



RN 776313-99-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)



RN 776314-00-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



RN 776314-01-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-03-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-44-4 CAPLUS
CN Butanoic acid, 4-[[5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]- (CA INDEX NAME)



RN 776314-68-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-amino-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)



IT 776313-93-0P 776313-95-2P 776314-06-8P
776314-07-9P 776314-09-1P 776314-11-5P
776314-13-7P 776314-15-9P 776314-16-0P
776314-18-2P 776314-20-6P 776314-21-7P
776314-22-8P 776314-23-9P 776314-25-1P
776314-26-2P 776314-27-3P 776314-29-5P
776314-31-9P 776314-33-1P 776314-35-3P
776314-36-4P 776314-38-6P 776314-39-7P
776314-41-1P 776314-46-6P 776314-48-8P
776314-50-2P 776314-52-4P 776314-54-6P
776314-56-8P 776314-58-0P 776314-60-4P
776314-62-6P 776314-64-8P 776314-66-0P
776314-70-6P 776314-72-8P 776314-74-0P
776314-76-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)
RN 776313-93-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2'-[2-(dimethylamino)ethoxy]-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776313-95-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 776314-06-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)



RN 776314-07-9 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)



RN 776314-09-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)



RN 776314-11-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



RN 776314-13-7 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-15-9 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-16-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)



RN 776314-18-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)



RN 776314-20-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)



RN 776314-21-7 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



RN 776314-22-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-23-9 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 776314-25-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-propoxy- (CA INDEX NAME)



RN 776314-26-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[3-(dimethylamino)propoxy]-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776314-27-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[3-(diethylamino)propoxy]-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)



RN 776314-29-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 776314-31-9 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-[(1-methylethyl)amino]propoxy]- (CA INDEX NAME)



RN 776314-33-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[3-[(2-hydroxyethyl)amino]propoxy]-6-methyl- (CA INDEX NAME)



RN 776314-35-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-[methyl(1-methylethyl)amino]propoxy]- (CA INDEX NAME)



RN 776314-36-4 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 776314-38-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-[(methylsulfonyl)amino]ethoxy]- (CA INDEX NAME)



RN 776314-39-7 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 776314-41-1 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-(4-morpholinyl)-2-oxoethoxy]- (CA INDEX NAME)



RN 776314-46-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(4-amino-4-oxobutoxy)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776314-48-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-(methylamino)-4-oxobutoxy]- (CA INDEX NAME)



RN 776314-50-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[4-(dimethylamino)-4-oxobutoxy]-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776314-52-4 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[4-(ethylamino)-4-oxobutoxy]-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776314-54-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-oxo-4-(1-pyrrolidinyl)butoxy]- (CA INDEX NAME)



RN 776314-56-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-(4-morpholinyl)-4-oxobutoxy]- (CA INDEX NAME)



RN 776314-58-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(4-hydroxybutoxy)-6-methyl- (CA INDEX NAME)



RN 776314-60-4 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[3-(1,3,4-oxadiazol-2-yl)propoxy]- (CA INDEX NAME)



RN 776314-62-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-(2,3-dihydroxypropoxy)-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)



RN 776314-64-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[[(2,2-dimethylpropyl)amino]methyl]-5-fluoro-6-methyl- (CA INDEX NAME)



RN 776314-66-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(hydroxymethyl)-6-methyl- (CA INDEX NAME)



RN 776314-70-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[(1-oxopropyl)amino]- (CA INDEX NAME)



RN 776314-72-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(acetylamino)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)



RN 776314-74-0 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[[(ethylamino)carbonyl]amino]-6-methyl- (CA INDEX NAME)



RN 776314-76-2 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[(methylsulfonyl)amino]- (CA INDEX NAME)



IT 776315-01-6P 776315-20-9P 776315-21-0P
776315-27-6P 776315-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)
RN 776315-01-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(3-bromopropoxy)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)



RN 776315-20-9 CAPLUS

CN Hydrazinecarboxylic acid, 2-[4-[[5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-1-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 776315-21-0 CAPLUS
CN Butanoic acid, 4-[[5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-, hydrazide (CA INDEX NAME)



RN 776315-27-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-formyl-6-methyl- (CA INDEX NAME)



RN 776315-29-8 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-nitro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:780670 CAPLUS
DOCUMENT NUMBER: 141:295874
TITLE: Preparation of tetrahydroquinoline derivatives as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system.
INVENTOR(S): Quan, Mimi L.; Wang, Cailan; Zhou, Jinglan; Hangeland, Jon J.; Seiffert, Dietmar A.; Knabb, Robert M.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004080971	A1	20040923	WO 2004-US7216		20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040235847	A1	20041125	US 2004-796396		20040309
US 7138412	B2	20061121			
EP 1601656	A1	20051207	EP 2004-719245		20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
JP 2006519844	T	20060831	JP 2006-507012		20040310
US 20060223854	A1	20061005	US 2006-430588		20060509
PRIORITY APPLN. INFO.:			US 2003-453812P	P	20030311
			US 2004-796396	A	20040309
			WO 2004-US7216	W	20040310

OTHER SOURCE(S): MARPAT 141:295874
GI



I

AB Title compds. [I; L1 = bond, CH2, CH2CH2, CH2O, CH2CO, etc.; L2 = bond, O, CO, CO2, S, SO, SO2, CONR8, SO2NR8, etc.; A = (substituted) carbocyclylene, heterocyclylene; B = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl; X1-X4 = CR1, CR2, N, etc.; R1 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NH2, alkylamino, dialkylamino, CONH2, CH2CH2NH2, etc.; R2 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NO2, amino, aminocarbonyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R4 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R5 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, heterocyclyl(alkyl), etc.; R13 = H, F, alkyl, aminoalkyl, CF3, aminocarbonyl, etc.; R14 = H, alkyl, aminoalkyl, F, CF3, aminocarbonyl, etc.; R13R14 = O; R15 = H, alkyl; R16 = H, alkyl, PhCH2, alkylcarbonyl, alkylsulfonyl, alkoxycarbonyl], were prepared Thus, 4-amidinobenzamidine monohydrochloride, styrene, 1'-formyl-1-benzyloxycarbonyl-4-isobutylcarbamoylbiphenyl (preparation given) and indium triflate were heated together at 70° in MeCN for 12 h to give a product which was hydrogenolyzed in MeOH/HOAc over Pd/C to give 2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl)-4-isobutylcarbamoylbiphenyl-2-carboxylic acid. I inhibited Factor XIa with Ki ≤15 μM.

IT 762253-64-5P 762253-65-6P 762253-68-9P
762253-69-0P 762253-70-3P 762253-71-4P
762253-73-6P 762253-76-9P 762253-77-0P
762253-78-1P 762253-79-2P 762253-80-5P
762253-81-6P 762253-82-7P 762253-83-8P
762253-84-9P 762253-86-1P 762253-87-2P
762253-88-3P 762253-89-4P 762253-91-8P
762253-92-9P 762253-93-0P 762253-94-1P
762253-95-2P 762253-96-3P 762253-97-4P
762254-16-0P 762254-17-1P 762254-19-3P
762254-69-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbaminidoyltetrahydroquinoline derivs. as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system)

RN 762253-64-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]- (CA INDEX NAME)



RN 762253-65-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)



RN 762253-68-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)



RN 762253-69-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)



RN 762253-70-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(1-oxopropyl)amino]- (CA INDEX NAME)



RN 762253-71-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(cyclopropylcarbonyl)amino]- (CA INDEX NAME)



RN 762253-73-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(1-oxobutyl)amino]- (CA INDEX NAME)



RN 762253-76-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-carboxyacetyl)amino]- (CA INDEX NAME)



RN 762253-77-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(carboxycarbonyl)amino]- (CA INDEX NAME)



RN 762253-78-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-(benzoylamino)- (CA INDEX NAME)



RN 762253-79-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-phenylacetyl)amino]- (CA INDEX NAME)



RN 762253-80-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-4-methyl-2-quinolinyl]-5'-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)



RN 762253-81-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxy-1-oxopropyl)amino]- (CA INDEX NAME)



RN 762253-82-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(4-carboxybenzoyl)amino]- (CA INDEX NAME)



RN 762253-83-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxybenzoyl)amino]- (CA INDEX NAME)



RN 762253-84-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-carboxybenzoyl)amino]- (CA INDEX NAME)



RN 762253-86-1 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[[4'-(aminocarbonyl)-5-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-2'-carboxy[1,1'-biphenyl]-3-yl]amino]carbonyl]- (CA INDEX NAME)



RN 762253-87-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[2-(2H-tetrazol-5-yl)acetyl]amino]- (CA INDEX NAME)



RN 762253-88-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(4-carboxy-1-oxobutyl)amino]- (CA INDEX NAME)



RN 762253-89-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2H-tetrazol-5-ylcarbonyl)amino]- (CA INDEX NAME)



RN 762253-91-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3,5-difluorobenzoyl)amino]- (CA INDEX NAME)



RN 762253-92-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[(3-amino-5-carboxybenzoyl)amino]-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]- (CA INDEX NAME)



RN 762253-93-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[1-oxo-3-(2H-tetrazol-5-yl)propyl]amino]- (CA INDEX NAME)



RN 762253-94-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxy-5-methylbenzoyl)amino]- (CA INDEX NAME)



RN 762253-95-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[3-carboxy-5-(1,1-dimethylethyl)benzoyl]amino]- (CA INDEX NAME)



RN 762253-96-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[[3-(aminocarbonyl)-5-carboxybenzoyl]amino]-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]- (CA INDEX NAME)



RN 762253-97-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[(ethylamino)carbonyl]amino]- (CA INDEX NAME)



RN 762254-16-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-64-5
CMF C33 H31 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 762254-17-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-65-6
CMF C36 H37 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 762254-19-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-68-9
CMF C36 H38 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 762254-69-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[3,5-bis(trifluoromethyl)benzoyl]amino]- (CA INDEX NAME)



IT 762254-61-5P 762254-62-6P 762254-67-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbaminidoyltetrahydroquinoline derivs. as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system)

RN 762254-61-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[1,2,3,4-tetrahydro-4-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)-4-phenyl-2-quinolinyl]-, phenylmethyl ester (CA INDEX NAME)



RN 762254-62-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[(3-methyl-1-oxobutyl)amino]-5'-[1,2,3,4-tetrahydro-4-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)-4-phenyl-2-quinolinyl]-, phenylmethyl ester (CA INDEX NAME)



RN 762254-67-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-(6-cyano-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl)-5'-[(3-methyl-1-oxobutyl)amino]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319702 CAPLUS
DOCUMENT NUMBER: 138:337841
TITLE: Preparation of 5'-carbamoyl-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
INVENTOR(S): Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford, Mark James; Cockerill, George Stuart; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003032972 A1 20030424 WO 2002-EP11577 20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002362895 A1 20030428 AU 2002-362895 20021016
EP 1435936 A1 20040714 EP 2002-801339 20021016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005511532 T 20050428 JP 2003-535776 20021016
US 20040267012 A1 20041230 US 2004-492698 20040415
US 7208629 B2 20070424
PRIORITY APPLN. INFO.: GB 2001-24941 A 20011017
WO 2002-EP11577 W 20021016
OTHER SOURCE(S): MARPAT 138:337841
GI



I



II

AB The title compds. [I; when m = 0-4, R1 = alkyl, cycloalkyl, alkenyl, etc.; and when m = 2-4, R1 addnl. = alkoxy, OH, etc.; R2 = H, alkyl, (CH2)ncycloalkyl; R3 = CONH(CH2)pR6; R6 = H, alkyl, cycloalkyl, etc.; U = Me, halo; W = Me, Cl; V, Y = H, Me, halo; m = 0-4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from alkyl; n = 0-3; p = 0-2; s = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepared E.g., a 3-step synthesis of the carboxamide II, starting from cyclopropylmethylamine and 4-bromobenzoyl chloride, was given.
IT 515135-12-3P 515135-23-6P 515135-24-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5'-carbamoyl-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)

RN 515135-12-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2',6-dimethyl- (CA INDEX NAME)



RN 515135-23-6 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-3'-fluoro-6-methyl- (CA INDEX NAME)



RN 515135-24-7 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2'-fluoro-6-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:107059 CAPLUS
DOCUMENT NUMBER: 136:151182
TITLE: Antimicrobial biaryl compounds
INVENTOR(S): Jefferson, Elizabeth Ann; Swayze, Eric
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009648	A2	20020207	WO 2001-US24067	20010801
WO 2002009648	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6849660	B1	20050201	US 2000-630122	20000801
CA 2418121	A1	20020207	CA 2001-2418121	20010801
AU 2001080944	A	20020213	AU 2001-80944	20010801
EP 1305028	A2	20030502	EP 2001-959380	20010801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004519421	T	20040702	JP 2002-515203	20010801

PRIORITY APPLN. INFO.: US 2000-630122 A 20000801
WO 2001-US24067 W 20010801

OTHER SOURCE(S): MARPAT 136:151182

GI



I



II

AB Biaryls I [X = CH, O, S, N, NH; Y = CH, N; n = 0, 1; one of R1 and R2 = (un)substituted CONRH2, COQNH2, CH2NH2, SO2NH2 and the other is H or R3; one of R5 and R6 = NHCOR7, NHSO2R7, NHS(O)R7 and the other is H, R4; Q = amino acid or peptide residue; R3 = H, halogen, (un)substituted NH2, NHCOR7; R4 = H, halogen, hydroxyl, amino, carboxyl, alkyl, alkenyl, alkynyl; R7 = H, amino, (un)substituted alkyl, alkenyl, alkynyl, 5-16 member carbocycle or heterocycle] were prepd for use as antimicrobial agents. Thus, polymer-supported piperazine was acylated with 5-bromo-2-thiophenecarboxylic acid, coupled with 3-H2NC6H4B(OH)2, and

acylated with 2,3-dioxobenzopyrazine-6-carboxylic acid to give the biaryl II. In a coupled bacterial transcription-translation assay II had an IC50 of 25 μM.

IT 395647-86-6P 395647-90-2P 395647-95-7P
395647-97-9P 395647-98-0P 395648-04-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminobiarylcarboxamides as bactericides)

RN 395647-86-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, N-[4-(aminocarbonyl)-3'-[(4-piperidinylcarbonyl)amino][1,1'-biphenyl]-2-yl]-1-ethyl-1,4-dihydro-7-methyl-4-oxo- (CA INDEX NAME)



RN 395647-90-2 CAPLUS
CN 1,3-Benzenedicarboxamide, N1-[4'-(aminocarbonyl)-2'-[[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl]amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 395647-95-7 CAPLUS
CN 1,3-Benzenedicarboxamide, N1-[2'-amino-4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 395647-97-9 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 4-amino-N-[4-(aminocarbonyl)-3'-[(4-piperidinylcarbonyl)amino][1,1'-biphenyl]-2-yl]-2-oxo- (CA INDEX NAME)



RN 395647-98-0 CAPLUS
CN 1H-Purine-1-acetamide, 6-amino-N-[4'-(aminocarbonyl)-2'-[(2-hydroxyacetyl)amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 395648-04-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-[[(2S)-2-amino-3-hydroxy-1-oxopropyl]amino]-2-[(2-hydroxyacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:767018 CAPLUS
Correction of: 1996:672852
DOCUMENT NUMBER: 135:273074
Correction of: 126:31466
TITLE: Boronic acid and ester inhibitors of thrombin
INVENTOR(S): Amparo, Eugene C.; Miller, William H.; Pacofsky, Gregory J.; Wityak, John; Weber, Patricia C.; Duncia, John J. V.; Santella, Joseph B., III
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, USA
SOURCE: U.S., 170 pp., Cont.-in-part of U.S. Ser. No. 348,029.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5563127	A	19961008	US 1994-364338	19941227
CA 2208971	A1	19960711	CA 1995-2208971	19951213
CA 2208971	C	20010116		
WO 9620689	A2	19960711	WO 1995-US16248	19951213
WO 9620689	A3	19961024		
W: AU, CA, JP, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9646404	A	19960724	AU 1996-46404	19951213
EP 810858	A2	19971210	EP 1995-944331	19951213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
ZA 9510978	A	19970627	ZA 1995-10978	19951227
US 5698538	A	19971216	US 1996-690220	19960726
PRIORITY APPLN. INFO.:			US 1993-36377	B2 19930324
			US 1994-318029	B2 19941004
			US 1994-348029	A2 19941201
			US 1994-364338	A 19941227
			WO 1995-US16248	W 19951213

AB Novel boronic acid and ester and carboxyl-modified amino acid compds. R1-Z-CHR2-A (A = organoboryl, BY1Y2; Y1, Y2 = independently OH, F, organoamino, C1-8 alkoxy, Y1Y2 = cyclic boron ester, amide containing N, S, O; etc.; Z = (CH2)mCX, X = amido, thioamido, etc., substituted C1-12 alkyl, alkenyl, etc.; R1 = arylalkenyl, aryl = substituted Ph, naphthyl,

biphenyl, etc.; R2 = substituted C1-12 alkyl, alkenyl, etc.), which are inhibitors of trypsin-like enzymes, are disclosed. Thus, amino acid modified boronic ester (Y1Y2 = (+)-pinanediol) was prepared in multiple steps starting from (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoyl)aminobutane-1-boronate. Thrombin inhibition activity of some of the compds. prepared is described.

IT 180897-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid-modified boronic acids and esters as inhibitors of thrombin)

RN 180897-16-9 CAPLUS

CN Carbamic acid, [4'-[[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:693143 CAPLUS
DOCUMENT NUMBER: 135:238672
TITLE: Functional radiographic imaging methods and agents
INVENTOR(S): Salb, Jesse; Cairns, Nick
PATENT ASSIGNEE(S): Veritas Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068151	A2	20010920	WO 2001-US8612	20010315
WO 2001068151	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6226352	B1	20010501	US 1998-149734	19980908
WO 2000013590	A2	20000316	WO 1999-US20298	19990831
WO 2000013590	A3	20000720		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

JP 2002524126	T	20020806	JP 2000-568401	19990831
US 20010001011	A1	20010510	US 2000-752619	20001229
US 6923950	B2	20050802		
US 20010031035	A1	20011018	US 2001-809870	20010315
US 6723746	B2	20040420		
EP 1263478	A2	20021211	EP 2001-920486	20010315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 20030091508	A1	20030515	US 2002-279811	20020614
US 20040170561	A1	20040902	US 2004-792155	20040302

PRIORITY APPLN. INFO.:

US 2000-190323P	P	20000316
US 1998-149734	A	19980908
WO 1999-US20298	W	19990831
US 2000-752619	A1	20001229
US 2001-809870	A1	20010315
WO 2001-US8612	W	20010315

OTHER SOURCE(S): MARPAT 135:238672

AB Systems and methods for radiog. imaging of tissue using a radio-opaque imaging agent that in one embodiment accumulates intracellularly in tissue in proportion to its functional, or physiol., activity. In one embodiment, the imaging agent is a cell membrane-permeable, radio-opaque, high affinity ligand for an intracellular target. The imaging agent is administered to a patient, and after an accumulation interval, radiog. images are acquired. The imaging agent preferentially accumulates in certain types of tissue and increases its radio-opacity. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a sep. radiog. image is acquired during transillumination by each beam. An image processing system may perform a weighted combination of the acquired images to produce a single displayed image. The system and method thus provides a functional image displayed with the anatomical detail and spatial resolution of a radiog. image. Functional and anatomical information are displayed in complete registration, facilitating localization of abnormal tissue in relation to nearby anatomical structures. An example of an application is the use of 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase and localization of malignant tissue, and in particular, breast cancer. The application may be further extended to imaging of nucleic acids and fatty acids in malignant tissues as well as other abnormal tissues.

IT 360779-16-4P 360779-17-5P 360779-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(functional radiog. imaging: 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)

RN 360779-16-4 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylamino)-2',4',6'-triiodo-3-nitro[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 360779-17-5 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylamino)-3-amino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 360779-20-0 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylmethylamino)-2',4',6'-triiodo-3,5-dinitro[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 360779-21-1P 360779-25-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(functional radiog. imaging: 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)
RN 360779-21-1 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylmethylamino)-3,5-diamino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 360779-25-5 CAPLUS
CN D-Glucose, 2-[[[3-amino-3',5'-bis[[(2,3-dihydroxypropyl)methylamino]carbonyl]-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 360779-26-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(functional radiog. imaging: 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)
RN 360779-26-6 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylamino)-3-amino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy-, labeled with iodine-123 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 360779-27-7 360779-28-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(functional radiog. imaging: 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)
RN 360779-27-7 CAPLUS
CN D-Glucose, 2-[[[3',5'-bis(acetylmethylamino)-3-amino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy-, labeled with iodine-123 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 360779-28-8 CAPLUS
CN D-Glucose, 2-[[[3-amino-3',5'-bis[[(2,3-dihydroxypropyl)methylamino]carbonyl]-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy-, labeled with iodine-123 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:529128 CAPLUS
DOCUMENT NUMBER: 131:184864
TITLE: Preparation of amidinophenylcarbamoylbiphenyl derivatives and heterocyclic analogs thereof as inhibitors of blood coagulation factor VIIa
INVENTOR(S): Senokuchi, Kazuhiko; Ogawa, Koji
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 665 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9941231	A1	19990819	WO 1999-JP622	19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9923006	A	19990830	AU 1999-23006	19990212
EP 1078917	A1	20010228	EP 1999-902896	19990212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ZA 9901273	A	19990825	ZA 1999-1273	19990217
US 6358960	B1	20020319	US 2000-601998	20000811
PRIORITY APPLN. INFO.:			JP 1998-76815	A 19980217
			WO 1999-JP622	W 19990212

OTHER SOURCE(S): MARPAT 131:184864

GI



I

AB The title compds. I [T1 = (R5)q; T2 = (R7)n; T3 = (R6)m; T4 = (R4)p; R1, R2 = H, alkoxycarbonyl, etc.; a proviso is given; R3 = H, alkyl, etc.; ring E1 = unsatd. heterocyclic ring, etc.; ring E2 = unsatd. heterocyclic ring, etc.; ring E3 = unsatd. or saturated heterocyclic ring, etc.; ring E3 may be omitted; ring E4 = unsatd. heterocyclic ring, etc.; R4, R5 = CO2R8, etc.; R8 = H, alkyl, etc.; p, q = 0, or 1, 2; p + q = 1 or 2; R6, R7 = H, alkyl, etc.; m = 1 - 3; n = 1 - 3] are prepared I are useful as preventives and/or remedies for various vascular lesions associating accelerated coagulation activity, for example, universal intravascular coagulation syndrome, coronary thrombosis, brain infarction, brain embolism, transient cerebral ischemic attack, diseases associating cerebral vascular disorders, deep vein thrombosis, peripheral embolism, thrombus formation following artificial blood vessel operation or artificial valve replacement, diseases associating postoperative thrombus formation, reobstruction and reconstriction following coronary artery bypass, reobstruction and reconstriction following PTCA or PTCR, thrombus formation during extracorporeal circulation and glomerulonephritis. Formulations containing a compound of this invention are given. In an in vitro test, 2-[2-(4-amidinophenylcarbamoyl)-6-methoxy-3-pyridyl]-5-[(1(S)-hydroxymethyl-2,2-dimethylpropyl)carbamoyl]benzoic acid methanesulfonic acid salt showed IC50 of 0.013 μM against factor VIIa.

IT 239458-88-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylcarbamoylbiphenyl derivs. and heterocyclic analogs thereof as inhibitors of blood coagulation factor VIIa)
RN 239458-88-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-5'-[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:299335 CAPLUS
DOCUMENT NUMBER: 129:28282
ORIGINAL REFERENCE NO.: 129:6037a,6040a
TITLE: Preparation and absorption spectrum studies of aromatic and alicyclic poly(amide acid) ammonium salts in water and DMF and in films
AUTHOR(S): Li, Qinghua; Yamashita, Takashi; Horie, Kazuyuki; Yoshimoto, Hiroshi; Miwa, Takao; Maekawa, Yasunari
CORPORATE SOURCE: Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, Tokyo, 113-8656, Japan
SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1998), 36(8), 1329-1340
CODEN: JPACEC; ISSN: 0887-624X
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of ammonium salts of poly(amide acid)s (PAS) were prepared from various poly(amide acid)s (PAA) with tertiary amines. The solubility of poly-(amide acid) ammonium salts prepared from PAA(PMDA/ODA) in water is related to the ion concentration of tertiary amines. In order to elucidate the influence of the chemical structures of poly(amide acid)s and poly(amide acid) ammonium salts on their absorption spectra, pyromellitic dianhydride (PMDA), 3,3',4,4'-biphenyltetracarboxylic dianhydride (BPDA), and

3,3',4,4'-benzophenonetetracarboxylic dianhydride (BTDA) were chosen to react with p-phenylenediamine (PDA) and (4,4'-diaminodicyclohexyl)methane (DCHM) to give three kinds of aromatic PAAs and three kinds of alicyclic PAAs. The corresponding PASs were prepared by the reaction of PAAs with triethanolamine (TEA). Their UV-visible (UV-vis) absorption spectra were investigated compared to those of model compds. A transparent film without absorption above 320 nm was obtained for PAS (PMDA/DCHM). The difference in absorption spectra of PAS(PMDA/PDA) from that of PAS(PMDA/DCHM) can be related to the existence of intra- and intermol. charge transfer (CT) for PAS(PMDA/PDA). The absorption spectra of PASs with PDA in films are red shifted compared to those of corresponding PAAs in films, while the absorption spectra of PASs in water are blue shifted compared to those of corresponding PAAs in DMF. No differences in the absorption spectra of PAAs and PASs were found in DMF/H2O (9/1) mixed solvent.

IT 207921-92-4P 207921-93-5P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(model compound; preparation and absorption spectrum studies of aromatic and alicyclic polyamic acid ammonium salts in water and DMF and in films)

RN 207921-92-4 CAPLUS
CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N3,N3',N4,N4'-tetraphenyl- (CA INDEX NAME)



RN 207921-93-5 CAPLUS
CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N3,N3',N4,N4'-tetracyclohexyl- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:672852 CAPLUS
DOCUMENT NUMBER: 126:31466
ORIGINAL REFERENCE NO.: 126:6405a,6408a
TITLE: Boronic acid and ester inhibitors of thrombin
INVENTOR(S): Amparo, Eugene C.; Miller, William H.; Pacofsky, Gregory J.; Wityak, John; Weber, Patricia C.; Duncia, John J. V.; Santella, Joseph B., III
PATENT ASSIGNEE(S): The Dupont Merck Pharmaceutical Company, USA
SOURCE: U.S., 170 pp., Cont.-in-part of U.S. Ser. No. 348,029.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5563127 A		19961008	US 1994-364338	19941227
PRIORITY APPLN. INFO.:			US 1993-36377	19930324
			US 1994-318029	19941004
			US 1994-348029	19941201

OTHER SOURCE(S): MARPAT 126:31466
GI



I

AB Novel boronic acid and ester and carboxyl-modified amino acid compds. R1-Z-CHR2-A (A = organoboryl, BY1Y2; Y1, Y2 = independently OH, F, organoamino, C1-8 alkoxy, Y1Y2 = cyclic boron ester, amide containing N, S, O; etc.; Z = (CH2)mCX, X = amido, thioamido, etc., substituted C1-12 alkyl, alkenyl, etc.; R1 = arylalkenyl, aryl = substituted Ph, naphthyl, biphenyl, etc.; R2 = substituted C1-12 alkyl, alkenyl, etc.), which are inhibitors of trypsin-like enzymes, are disclosed. Thus, amino acid modified boronic ester I (Y1Y2 = (+)-pinanediol) was prepared in multiple steps starting from (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoyl)aminobutane-1-boronate. Thrombin inhibition activity of some of the compds. prepared is described.

IT 180897-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid-modified boronic acids and esters as inhibitors of thrombin)

RN 180897-16-9 CAPLUS

CN Carbamic acid, [4'-[[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:557907 CAPLUS

DOCUMENT NUMBER: 125:222432

ORIGINAL REFERENCE NO.: 125:41597a,41600a

TITLE: Preparation of α-aminoboronic acid and ester as inhibitors of thrombin

INVENTOR(S): Amparo, Eugene Cruz; Miller, William Henry; Pacofsky, Gregory James; Wityak, John; Weber, Patricia Carol; Duncia, John Jonas Vytautas; Santella, Joseph Basil, III

PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620689	A2	19960711	WO 1995-US16248	19951213
WO 9620689	A3	19961024		
W: AU, CA, JP, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5563127	A	19961008	US 1994-364338	19941227
AU 9646404	A	19960724	AU 1996-46404	19951213
EP 810858	A2	19971210	EP 1995-944331	19951213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				

PRIORITY APPLN. INFO.:	US 1994-364338	A	19941227
	US 1993-36377	B2	19930324
	US 1994-318029	B2	19941004
	US 1994-348029	A2	19941201
	WO 1995-US16248	W	19951213

OTHER SOURCE(S): MARPAT 125:222432

AB Novel boronic acid and ester and carboxyl-modified amino acid compds. of formula R1-Z-CHR1-A [A = BY1Y2, CO CF3, CO2R3, COCO2R3, COCOR3, PO3H2, CHO, etc.; wherein Y1, Y2 = OH, F, NR3R4, C1-8 alkoxy; or Y1 and Y2 are taken together to form a cyclic boron ester, cyclic boron amide, or cyclic boron amide ester containing 2-20 C atoms and 0-3 heteroatoms selected from N, S, or S; R3 = H, C1-8 alkyl, aryl-C1-4 alkyl, C5-7 cycloalkyl, Ph; R4 = group listed in R3, phenylsulfonyl; Z = (CH2)m CON R8, (CH2)m C(S)NR8, (CH2)m CO2, (CH2)m C(S)O, (CH2)mSO2O; wherein m = 0-6 and R8 = H, ring-(un)substituted phenylalkyl, C3-7 cycloalkyl, C1-8 alkyl; R1 = ring-substituted arylalkyl or heteroaryl, etc.; R2 = substituted C1-12 alkyl or C2-12 alkenyl, (substituted alkyl)phenylalkyl], which are inhibitors of trypsin-like enzymes, notably blood coagulation proteases such as human thrombin, factor VIIa, factor IXa, factor Xa, plasma kallikrein, and plasmin, and are useful for the treatment of thrombosis and inflammation or as anticoagulants for the processing of blood for therapeutic or diagnostic purposes or for the production of blood products or fragments, are prepared Thus, (+)-pinanediol 4-bromo-1(R)-aminobutane-1-boronate hydrochloride was acylated by 4-phenylbenzoyl chloride in the presence of N-methylmorpholine in CH2Cl2 to give (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoylamino)butane-1-boronate, which underwent azidolysis with NaN3 in DMF at 70° for 2 h to give (+)-pinanediol 4-azido-1(R)-(4-phenylbenzoylamino)butane-1-boronate, and catalytic hydrogenation in the presence of Pd(OH)2/C in a mixture of MeOH and 1 M aqueous HCl to give (+)-pinanediol 4-amino-1(R)-(4-phenylbenzoylamino)butane-1-boronate, i.e., N1-(4-phenylbenzoyl)boroornithine (+)-pinanediol ester hydrochloride, followed by condensation with aminoiminomethanesulfonic acid in the presence of 4-dimethylaminopyridine in ethanol at reflux of 3 h to give N-(4-phenylbenzoyl)boroarginine (+)-pinanediol ester, bisulfite. The latter compound in vitro inhibited human thrombin and factor Xa with Ki value of <500 and 50,000 nM, resp.

IT 180897-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α-aminoboronic acids and esters as inhibitors of blood coagulation proteases for disease therapy)

RN 180897-16-9 CAPLUS

CN Carbamic acid, [4'-[[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-

hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:340537 CAPLUS
DOCUMENT NUMBER: 122:134119
ORIGINAL REFERENCE NO.: 122:25027a,25030a
TITLE: Manufacture of silicon-containing polyfunctional carboxylic acid amides and their curing materials with good hardness and adhesion
INVENTOR(S): Kunimune, Koichi; Aono, Toshiharu; Watanabe, Eiji
PATENT ASSIGNEE(S): Chisso Corp, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06157556	A	19940603	JP 1992-255571	19920831
JP 3626214	B2	20050302		

PRIORITY APPLN. INFO.: JP 1992-255571 19920831

AB The amides are prepared by the reaction of silanes and polyfunctional carboxylic acids. Reaction of aminophenyltrimethoxysilane and 3,3'4,4'-benzophenonetetracarboxylic dianhydride, dehydration, coating on a wafer, and curing gave samples showed good adhesion and pencil hardness ≥9 H.

IT 160767-12-4P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(manufacture of silicon-containing polyfunctional carboxylic acid amides and their curing materials with good hardness and adhesion)

RN 160767-12-4 CAPLUS
CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N,N',N'',N'''-tetrakis[(trimethoxysilyl)phenyl]-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 344800-32-4
CMF C52 H62 N4 O16 Si4
CCI IDS

PAGE 1-A



PAGE 2-A



L6 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:76159 CAPLUS
DOCUMENT NUMBER: 108:76159
ORIGINAL REFERENCE NO.: 108:12615a,12618a
TITLE: Proton NMR spectroscopic study of the isomeric composition of aromatic polyamic acids
AUTHOR(S): El'mesov, A. N.; Bogachev, Yu. S.; Zhuravleva, I. L.; Kardash, I. E.
CORPORATE SOURCE: Fiz.-Khim. Inst. im. Karpova, Moscow, USSR
SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A (1987), 29(11), 2333-9
CODEN: VYSAAF; ISSN: 0507-5475
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB NMR spectroscopy of a series of polyamic acids prepared by polycondensation of dianhydrides of different aromatic tetracarboxylic acids (3,3',4,4'-diphenyl sulfone tetracarboxylic dianhydride,

3,3',4,4'-benzophenonetetracarboxylic dianhydride, 3,3',4,4'-diphenyltetracarboxylic dianhydride, 3,3',4,4'-diphenyl oxide tetracarboxylic dianhydride) with different diamines (p-phenylenediamine, p-benzidine, 4,4'-diaminodiphenylmethane, 4,4'-diaminodiphenyl oxide, 4,4'-diaminodiphenyl sulfone) showed that the isomer composition of the products depended on the nature of the bridge unit in the dianhydride. The presence of electron-acceptor units in the dianhydride led to enrichment of the polymer by m-isomer structures, whereas units with electron-donor properties increased the concentration of p-isomer in the polymer.

In the case of lack of a bridge unit, approx. equal. amts. of both isomers were formed. The chemical structure of the diamines did not affect significantly the isomer composition of the polyamic acids.

IT 112824-09-6
RL: PRP (Properties)
(structure of, as model for aromatic polyamic acids)

RN 112824-09-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxylic acid, 3',4-bis[[(4-methoxyphenyl)amino]carbonyl]- (CA INDEX NAME)



L6 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:600516 CAPLUS

DOCUMENT NUMBER: 105:200516

ORIGINAL REFERENCE NO.: 105:32195a,32198a

TITLE: Fine insulator pattern formation

INVENTOR(S): Kataoka, Fumio; Shoji, Fusaji

PATENT ASSIGNEE(S): Hitachi, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61067228	A	19860407	JP 1984-187916	19840910

PRIORITY APPLN. INFO.: JP 1984-187916 19840910

GI



I

AB The claimed patterning process involves the following steps: (1) formation of a polyimide insulator layer on a substrate; (2) coating of the insulator layer with a Si-containing polyimide precursor type photosensitive (or radiation-sensitive) layer; (3) drying of the photosensitive layer at 50-120°; (4) patternwise exposure of the photosensitive layer; (5) development; (6) hardening of the pattern at 150-500° to form a polyimide pattern; and (7) O plasma treatment to improve the plasma etching resistance of the polyimide pattern and to etch the polyimide insulator layer to give a 2-layer structured insulator pattern. Thus, a Si substrate was coated with P/Q (a polyimide), then coated with a polyimide precursor having repeating units of the formula I, dried at 70°, imagewise exposed to deep UV, developed, heated at 350°, and etched in an O plasma to give a fine polyimide pattern.

IT 105062-28-0
RL: USES (Uses)
(resist composition containing, for polyimide insulator pattern formation)

RN 105062-28-0 CAPLUS

CN Poly[oxy(dimethylsilylene)-1,3-propanediyliminocarbonyl[4,4'-bis[[[2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl]amino]carbonyl][1,1'-biphenyl]-3,3'-diyl]carbonylimino-1,3-propanediyl(dimethylsilylene)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

n

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.31	307.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-18.40	-18.40

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:34 ON 27 AUG 2008